{
    "clinical_study": {
        "@rank": "25052", 
        "arm_group": {
            "arm_group_label": "Melflufen and dexamethasone in combination", 
            "arm_group_type": "Experimental", 
            "description": "Intravenous infusion of melflufen Day 1 of 21 day cycles, in combination with 40 mg dexamethasone (oral or i.v.) day 1, 8 and 15 of the 21 day cycles."
        }, 
        "brief_summary": {
            "textblock": "The study will explore escalating doses of melflufen in combination with dexamethasone in\n      small groups of patients to find the maximum tolerated dose of melflufen. That dose will\n      then be used to determine the efficacy and safety profile of melflufen in combination with\n      dexamethasone in a larger group of patients."
        }, 
        "brief_title": "Safety and Efficacy of Melflufen and Dexamethasone in Relapsed and/or Relapsed-Refractory Multiple Myeloma Patients", 
        "completion_date": {
            "#text": "May 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Relapsed and/or Relapsed-refractory Multiple Myeloma", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male or female, age 18 years or older\n\n          2. Patient has a diagnosis of multiple myeloma with documented relapsed and/or\n             relapsed-refractory disease\n\n          3. Patient has measurable disease defined as any of the following:\n\n               1. Serum monoclonal protein \u2265 0.5 g/dL by protein electrophoresis\n\n               2. \u2265200 mg of monoclonal protein in the urine on 24-hour electrophoresis\n\n               3. Serum immunoglobulin free light chain \u226510 mg/dL AND abnormal serum\n                  immunoglobulin kappa to lambda free light chain ratio\n\n               4. If no monoclonal protein is detected, then \u2265 30% monoclonal bone marrow plasma\n                  cells\n\n          4. Patient has had at least 2 or more prior lines of therapy\n\n          5. Life expectancy of \u22656 months\n\n          6. Patient has an ECOG performance status \u2264 2 (Patients with lower performance status\n             based solely on bone pain secondary to multiple myeloma will be eligible)\n\n          7. Females of childbearing potential must have a negative serum or urine pregnancy test\n             prior to patient registration\n\n          8. Female patients of child bearing potential and non-vasectomized male patients agree\n             to practice appropriate methods of birth control\n\n          9. Ability to understand the purpose and risks of the study and provide signed and dated\n             informed consent and authorization to use protected health information\n\n         10. The patient has, or accepts to have, an acceptable infusion device for infusion of\n             melflufen\n\n         11. 12 lead ECG with QtcF interval \u2264 470 msec\n\n         12. The following laboratory results must be met within 21 days of patient registration:\n\n               -  Absolute neutrophil count \u2265 1,000 cells/dL (1.0 x 109/L)\n\n               -  Platelet count \u2265 75,000 cells/dL (75 x 109/L)\n\n               -  Hemoglobin \u2265 8.0 g/dL\n\n               -  Total Bilirubin \u2264 1.5 x upper limit of normal\n\n               -  Renal function: Estimated creatinine clearance \u2265 45 ml/min or serum creatinine \u2264\n                  2.5 mg/dL\n\n               -  AST (SGOT) and ALT (SGPT) \u2264 3.0 x ULN\n\n        Exclusion Criteria:\n\n          1. Patient has evidence of mucosal or internal bleeding and/or is platelet transfusion\n             refractory\n\n          2. Any medical conditions that, in the Investigator's opinion, would impose excessive\n             risk to the patient or would adversely affect his/her participation in this study\n\n          3. Known active infection requiring parenteral or oral anti-infective treatment\n\n          4. Other malignancy within the past 3 years with the exception of adequately treated\n             basal cell carcinoma, squamous cell skin cancer, carcinoma in-situ of the cervix\n\n          5. Other ongoing anti-myeloma therapy. Patients may be receiving concomitant therapy\n             with bisphosphonates and low dose corticosteroids for symptom management and comorbid\n             conditions. Doses of corticosteroid should be stable for at least 7 days prior to\n             patient registration.\n\n          6. Pregnant or breast-feeding females\n\n          7. Serious psychiatric illness, active alcoholism, or drug addiction that may hinder or\n             confuse follow-up evaluation\n\n          8. Known HIV or hepatitis B or C viral infection\n\n          9. Patient has concurrent symptomatic amyloidosis or plasma cell leukemia\n\n         10. POEMS syndrome\n\n         11. Previous cytotoxic therapies, including cytotoxic investigational agents, for\n             multiple myeloma within 3 weeks (6 weeks for nitrosoureas) prior to start of study\n             treatment. Biologic, novel therapy (including investigational agents in this class)\n             or corticosteroids within 2 weeks prior to patient registration. Patient has side\n             effects of the previous therapy > grade 1 or previous baseline.\n\n         12. Prior peripheral stem cell transplant within 12 weeks of patient registration\n\n         13. Radiotherapy within 21 days prior to Cycle 1 Day 1. However, if the radiation portal\n             covered \u2264 5% of the bone marrow reserve, the patient may be enrolled irrespective of\n             the end date of radiotherapy\n\n         14. Known intolerance to steroid therapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01897714", 
            "org_study_id": "O-M1-12"
        }, 
        "intervention": [
            {
                "arm_group_label": "Melflufen and dexamethasone in combination", 
                "intervention_name": "Melflufen", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Melflufen and dexamethasone in combination", 
                "intervention_name": "Dexamethasone", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Dexamethasone acetate", 
                "Dexamethasone", 
                "Dexamethasone 21-phosphate", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 13, 2014", 
        "location": [
            {
                "contact": {
                    "email": "trials@oncopeptides.se"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Dana Farber Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Claudia E Paba Prada, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "trials@oncopeptides.se"
                }, 
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27514"
                    }, 
                    "name": "Universtity of North Carolina"
                }, 
                "investigator": {
                    "last_name": "Peter Voorhees, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "trials@oncopeptides.se"
                }, 
                "facility": {
                    "address": {
                        "city": "Vejle", 
                        "country": "Denmark"
                    }, 
                    "name": "Vejle Hospital"
                }, 
                "investigator": {
                    "last_name": "Torben Plesner, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "trials@oncopeptides.se"
                }, 
                "facility": {
                    "address": {
                        "city": "Turin", 
                        "country": "Italy"
                    }, 
                    "name": "Turin Hospital Myeloma Unit"
                }, 
                "investigator": {
                    "last_name": "Antonio Palumbo, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "trials@oncopeptides.se"
                }, 
                "facility": {
                    "address": {
                        "city": "Rotterdam", 
                        "country": "Netherlands"
                    }, 
                    "name": "Erasmus University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Pieter Sonneveld, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "trials@oncopeptides.se"
                }, 
                "facility": {
                    "address": {
                        "city": "Gothenburg", 
                        "country": "Sweden"
                    }, 
                    "name": "Sahlgrenska Hospital"
                }, 
                "investigator": {
                    "last_name": "Ulf-Henrik Mellqvist, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Denmark", 
                "Italy", 
                "Netherlands", 
                "Sweden"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-Label Phase I/IIa Study of the Safety and Efficacy of Melphalan-flufenamide (Melflufen) and Dexamethasone Combination for Patients With Relapsed and/or Relapsed-Refractory Multiple Myeloma", 
        "overall_contact": {
            "email": "trials@oncopeptides.se", 
            "last_name": "Eva Nordstr\u00f6m, MSc Pharm", 
            "phone": "+46 70 634 02 11"
        }, 
        "overall_official": [
            {
                "affiliation": "Dana Farber Cancer Institute, Boston MA, USA", 
                "last_name": "Paul G Richardson, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Oncopeptides AB, Stockholm, Sweden", 
                "last_name": "Johan Harmenberg, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Quintiles Inc, Reading, United Kingdom", 
                "last_name": "Hassan Aly, MD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Sweden: Medical Products Agency", 
                "Denmark: Danish Health and Medicines Authority", 
                "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
                "Italy: The Italian Medicines Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "The primary objective of the Phase I portion of the study is to determine the Maximum Tolerated Dose (MTD) of the combination of melflufen and dexamethasone in patients with relapsed and/or relapsed-refractory Multiple Myeloma.", 
                "safety_issue": "Yes", 
                "time_frame": "21 days"
            }, 
            {
                "measure": "The primary objective of the Phase IIa part is to evaluate the objective response rate to the combination of melflufen and dexamethasone at the MTD determined in the Phase I part", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01897714"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Oncopeptides AB", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Oncopeptides AB", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}